Development of Phenotypic and Genotypic Resistance to Antiretroviral Therapy in the UNAIDS HIV Drug Access Initiative – Uganda

dc.contributor.authorWeidlea, J. Paul
dc.contributor.authorDowningb, Robert
dc.contributor.authorSozic, Catherine
dc.contributor.authorMwebaze, Raymond
dc.contributor.authorRukundo, Gideon
dc.contributor.authorMalamba, Samuel
dc.contributor.authorRespessa, Richard
dc.contributor.authorHertogsf, Kurt
dc.contributor.authorLarderg, Brendan
dc.contributor.authorOchola, Dorothy
dc.contributor.authorMermin, Jonathan
dc.contributor.authorBadara Sambk, Badara
dc.contributor.authorLackritz, Eve
dc.date.accessioned2021-04-21T13:34:14Z
dc.date.available2021-04-21T13:34:14Z
dc.date.issued2003-07
dc.description.abstractObjective: We describe phenotypic drug resistance, response to therapy, and geno-typic mutations among HIV-infected patients in Uganda taking antiretroviral medica-tions for ≥ 90 days who had a viral load ≥ 1000 copies/ml. Methods: HIV-1 group and subtype, virologic and immunologic responses to anti-retroviral therapy, phenotypic resistance to antiretroviral drugs, and associated geno-typic mutations among patients at three treatment centers in Uganda between June 1999 and August 2000 were assessed. Therapy was two nucleoside reverse tran-scriptase inhibitors (NRTIs) or highly active antiretroviral therapy (HAART). Results: All HIV identified was HIV-1, group M, subtypes A, C, and D. Sixty-one (65%) of 94 patients with a phenotypic resistance result had evidence of phenotypic resistance including resistance to a NRTI for 51 of 92 (55%) taking NRTIs, to a non-nucleoside reverse transcriptase inhibitor (NNRTI) for nine of 16 (56%) taking NNRTIs, and to a protease inhibitor (PI) for eight of 37 (22%) taking PIs. At the time of the first specimen with resistance, the median change from baseline viral load was –0.56 log copies/ml [interquartile range (IQR), –1.47 to +0.29] and CD4+ cell count was +35 × 106 cells/l (IQR, –18 to +87). Genotypic resistance mutations, matched with phenotypic resistance assay results and drug history, were generally consistent with those seen for HIV-1, group M, subtype B infections in industrialized countries. Conclusion: Initial phenotypic resistance and corresponding genotypic mutations among patients treated in Uganda were similar to those with subtype B infections in North America and Europe. These data support policies that promote the use of HAART regimens against HIV-1, group M, non-B subtypes in a manner consistent with that used for subtype B infections.en_US
dc.identifier.citationWeidle, P.J., Downing, R., Sozi, C., Mwebaze, R., Rukundo, G., Malamba, S., Respess, R., Hertogs, K., Larder, B., Ochola, D. and Mermin, J., 2003. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative–Uganda. Aids, 17, pp.S39-S48.en_US
dc.identifier.issn1473-5571
dc.identifier.issn0269-9370
dc.identifier.urihttp://hdl.handle.net/20.500.12280/2681
dc.language.isoenen_US
dc.publisherWolters Kluwer Health, Inc.en_US
dc.relation.ispartofseriesAids;17
dc.subjectAfricaen_US
dc.subjectAntiretroviralen_US
dc.subjectHIVen_US
dc.subjectResistanceen_US
dc.subjectSubtypesen_US
dc.subjectUgandaen_US
dc.titleDevelopment of Phenotypic and Genotypic Resistance to Antiretroviral Therapy in the UNAIDS HIV Drug Access Initiative – Ugandaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Mwebaze_ARTICLE_MKPGS_2003_Development.pdf
Size:
29.1 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: